Immunoprecise Antibodies Ltd
NASDAQ:HYFT

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
NASDAQ:HYFT
Watchlist
Price: 1.37 USD -8.05% Market Closed
Market Cap: $64m

Wall Street
Price Targets

HYFT Price Targets Summary
Immunoprecise Antibodies Ltd

Wall Street analysts forecast HYFT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HYFT is 4.08 USD with a low forecast of 3.03 USD and a high forecast of 5.25 USD.

Lowest
Price Target
3.03 USD
121% Upside
Average
Price Target
4.08 USD
198% Upside
Highest
Price Target
5.25 USD
283% Upside
Immunoprecise Antibodies Ltd Competitors:
Price Targets
DVN
Devon Energy Corp
6% Upside
BSRR
Sierra Bancorp
3% Upside
SDA
Goldenbridge Acquisition Ltd
142% Upside
WEED
Canopy Growth Corp
131% Upside
0IF
LogicBio Therapeutics Inc
79% Upside
DHR
Danaher Corp
27% Upside
TES
Tesmec SpA
-16% Downside

Revenue
Forecast

N/A
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

The compound annual growth rate of Immunoprecise Antibodies Ltd's revenue for the next 3 years is 11%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HYFT's stock price target?
Price Target
4.08 USD

According to Wall Street analysts, the average 1-year price target for HYFT is 4.08 USD with a low forecast of 3.03 USD and a high forecast of 5.25 USD.

What is Immunoprecise Antibodies Ltd's Revenue forecast?
Projected CAGR
11%

The compound annual growth rate of Immunoprecise Antibodies Ltd's revenue for the next 3 years is 11%.

Back to Top